



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/820,832	03/30/2001	J. T. Lin		3717

7590 01/17/2003

KNOBBE, MARTENS, OLSON & BEAR, LLP  
620 NEWPORT CENTER DRIVE  
SIXTEENTH FLOOR  
NEWPORT BEACH, CA 92660

EXAMINER

FARAH, AHMED M

ART UNIT

PAPER NUMBER

3739

DATE MAILED: 01/17/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

# Office Action Summary

Application No.

09/820,832

Applicant(s)

T. J. Lin

Examiner

A. Farah

Art Unit

3739



-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

## Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE three MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

## Status

- 1) ☒ Responsive to communication(s) filed on Oct 29, 2002
- 2a) ☐ This action is FINAL. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11; 453 O.G. 213.

## Disposition of Claims

- 4) ☒ Claim(s) 1-20 is/are pending in the application.
- 4a) Of the above, claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 1-20 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claims \_\_\_\_\_ are subject to restriction and/or election requirement.

## Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) ☐ The proposed drawing correction filed on \_\_\_\_\_ is: a) ☐ approved b) ☐ disapproved by the Examiner.  
If approved, corrected drawings are required in reply to this Office action.
- 12) ☐ The oath or declaration is objected to by the Examiner.

## Priority under 35 U.S.C. §§ 119 and 120

- 13) ☐ Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  
a) ☐ All b) ☐ Some\* c) ☐ None of:  
1. ☐ Certified copies of the priority documents have been received.  
2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_  
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).  
\*See the attached detailed Office action for a list of the certified copies not received.
- 14) ☐ Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).  
a) ☐ The translation of the foreign language provisional application has been received.
- 15) ☐ Acknowledgement is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

## Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892) 4) ☐ Interview Summary (PTO-413) Paper No(s). \_\_\_\_\_
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948) 5) ☐ Notice of Informal Patent Application (PTO-152)
- 3) ☐ Information Disclosure Statement(s) (PTO-1449) Paper No(s). \_\_\_\_\_ 6) ☐ Other: \_\_\_\_\_

Art Unit: 3739

## DETAILED ACTION

### *Double Patenting*

1. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper tames extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970);and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321© may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

2. Claims 1, 3-5, and 12-14, and 18-20 are again rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-15 of U.S.

Patent No. 6,258,082 B1. Although the conflicting claims are not identical, they are not patentably distinct from each other because they teach analogous ophthalmic laser surgery methods for treating presbyopic patient comprising the steps of providing ablative laser beams in the UV and in the IR wavelengths; and directing the ablative laser to the presbyopic eye to treat presbyopia.

3. A rejection based on double patenting of the "same invention" type finds its support in the language of 35 U.S.C. 101 which states that "whoever invents or discovers any new and useful process ... may obtain a patent therefor ..." (Emphasis added). Thus, the term "same invention,"

Art Unit: 3739

in this context, means an invention drawn to identical subject matter. See *Miller v. Eagle Mfg. Co.*, 151 U.S. 186 (1894); *In re Ockert*, 245 F.2d 467, 114 USPQ 330 (CCPA 1957); and *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970).

A statutory type (35 U.S.C. 101) double patenting rejection can be overcome by canceling or amending the conflicting claims so they are no longer coextensive in scope. The filing of a terminal disclaimer cannot overcome a double patenting rejection based upon 35 U.S.C. 101.

4. Claims 1, 3-6, 11-14, and 18-20 are provisionally rejected under 35 U.S.C. 101 as claiming the same invention as that of claims 1, 2, 4-10, 20, and 23-25 of copending Application No. 09/794,496. This is a provisional double patenting rejection since the conflicting claims have not in fact been patented.

### *Claim Rejections - 35 USC § 102*

5. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless --

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

(e) the invention was described in a patent granted on an application for patent by another filed in the United States before the invention thereof by the applicant for patent, or on an international application by another who has fulfilled the requirements of paragraphs (1), (2), and (4) of section 371© of this title before the invention thereof by the applicant for patent.

6. Claims 1, 3, 4, 11-13, and 17-20 are again rejected under 35 U.S.C. 102(b) as being anticipated by Schachar U.S. Patent No. 5,503,165.

Art Unit: 3739

Schachar discloses an ophthalmic surgery method for treating presbyopic patient by increasing the effective working distance of the ciliary muscle and the zonular fibers connected to the corneal lens of the eye. Here, 'the increase of the effective working distance of the ciliary muscle and zonular fibers' is treated to be analogous to the increase "via the movement of the ciliary body and zonal fiber," *as claimed*. Schachar teaches that the increase of the ciliary muscle movement is accomplished by manipulation of the zonulas with an external means such as surgical procedures, treatment with enzymes, heat or optical irradiation.

As to the limitation "*movement of the ciliary body is provided by the increase of the flexibility of said laser beam ablated sclera tissue which is filled in by sub-conjunctival tissue*" in claim 1, ablating sclera tissue would inherently/automatically result in the area being filled in by portion of the conjunctiva that is proximal to the sclera, i.e., the sub-conjunctival tissue, as presently claimed.

In reference to claims 11-13, Schachar describes various laser sources that are suitable for the treatment including UV and IR lasers (see claims 12-31).

7. Claims 1, 3, 4, 11-13, and 17-20 are rejected under 35 U.S.C. 102(b) as being anticipated by Schachar U.S. Patent 5,489,299.

Schachar discloses the removal of sclera tissue in a predetermined pattern by ablating corneal tissue using one of a variety of lasers, including YAG laser (Col. 8, lines 10-18). As to the limitation that '*subconjunctival tissue replaces the removed sclera tissue, increasing the*

Art Unit: 3739

*flexibility and movement of the ciliary body*' recited in claim 1, the portion of the conjunctival tissue that is proximal to the removed sclera (sub-conjunctival tissue) inherently fills the void.

8. Claims 1, 3-5, 12-14, and 18-20 are again rejected under 35 U.S.C. 102(e) as being anticipated by Lin (U.S. Pat. No. 6,258,082 B1).

Lin discloses ophthalmic surgery system and methods for treating presbyopic patient comprising the steps of providing ablative laser (UV and IR lasers); and directing the ablative laser to the presbyopic eye to treat presbyopia.

### ***Claim Rejections - 35 USC § 103***

9. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

10. Claims 5, 7-10, 14-20 are again rejected under 35 U.S.C. 103(a) as being unpatentable over Schachar in view of Odrich et al. (U.S. Pat. No. 6,280,435).

Schachar, described above, does not teach a method of scanning the treatment laser beams in a predetermined patterns around the area of the cornea.

However, Odrich et al. disclose an alternative method and systems for laser treatment of presbyopic comprising the step of scanning ablative laser in a preselected pattern to ablate predetermined portions of the corneal. They teach that the scanning is performed by using

Art Unit: 3739

optical scanning elements such as rotating mirror and prisms (Col. 17, lines 60-64). They further teach the use of rotatable masks, variable width slits, and variable diameter iris diaphragms to generate the predetermined patterns. In reference to claim 9, Odrich et al. disclose translation device used for the scanning (see Col. 11, lines 8-16).

Therefore, it would have been obvious to one skilled in the art at the time of the applicant's invention to modify Schachar in view of Odrich et al. to scanning ablative laser in a preselected pattern in order to ablate predetermined portions of the corneal, and to use variable aperture devices in order to shape the ablative light to produce the predetermined patterns.

### ***Conclusion***


Any inquiry concerning this communication or earlier communications from the examiner should be directed to A. Farah whose telephone number is (703) 305-5787. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ms. Linda Dvorak, can be reached on (703) 308-0994. The fax number for the Examiner is (703)746-3368.

**A. M. Farah**

**Patent Examiner** (Art Unit 3739)



January 12, 2003



**Supervisory Patent Examiner**